BioCentury
ARTICLE | Clinical News

Imetelstat: Additional Phase II data

September 7, 2015 7:00 AM UTC

Additional data from an investigator-sponsored, open-label, U.S. Phase II trial in 33 patients with intermediate-2 or high-risk primary or secondary MF showed that IV 9.4 mg/kg imetelstat led to an OR...